ARTICLE | Company News
Sanofi sales and marketing update
December 15, 2014 8:00 AM UTC
Sanofi’s Genzyme Corp. launched Lemtrada alemtuzumab in the U.S. to treat relapsing forms of multiple sclerosis (MS). The wholesale acquisition cost (WAC) for 1.2 mL of 10 mg/mL solution is $19,750....